GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » 3-Year FCF Growth Rate

Spero Therapeutics (STU:2HA) 3-Year FCF Growth Rate : 45.50% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics 3-Year FCF Growth Rate?

Spero Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-0.30.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 45.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Spero Therapeutics was 58.00% per year. The lowest was -20.80% per year. And the median was 25.85% per year.


Competitive Comparison of Spero Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Spero Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's 3-Year FCF Growth Rate falls into.



Spero Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Spero Therapeutics  (STU:2HA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Spero Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Spero Therapeutics (STU:2HA) Business Description

Traded in Other Exchanges
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines